Does E80.0 require prior authorization?

No, E80.0 does not require prior authorization (high confidence). Covered without prior authorization.

`E80.0`, Hereditary erythropoietic porphyria

ICD-10-CM

No Prior Auth Required

Covered without prior authorization (high confidence)

Supportive documentation evidencing the condition and treatment must be documented in the medical record and be available to the Contractor upon request.
ICD-10-CM diagnosis codes supporting the medical necessity of the service must be submitted with each claim.
High-utilization or repeat testing should include clinical justification in the record (for example, repeat testing due to unsatisfactory response to treatment) to support medical necessity.
Submission of medical records (e.g., chart notes, laboratory values, etc.) to support the diagnosis of erythropoietic protoporphyria (EPP).

Allergy testing for inhalant allergens is covered when medically necessary; evaluation may include up to 90 prick-puncture tests followed by up to 40 intracutaneous tests if prick/puncture results are negative.
Allergy testing for food sensitivity is covered when medically necessary and may require up to 40 percutaneous tests.
Multitest intracutaneous testing of up to 60 tests may be appropriate in lieu of prick-puncture testing for selected patients (for example, young children, older adults, or needle-phobic individuals).
Exceeding the stated testing parameters may be covered when preliminary testing failed and immunotherapy failed to control symptoms, provided documentation supports medical necessity.
Initial therapy with Givlaari is medically necessary for adults with acute hepatic porphyria (AHP) when: diagnosis of AHP is established; and the patient has active disease defined by at least 2 porphyria attacks in the past 6 months, OR patient is on prophylactic hemin with documented baseline hemin requirements and attack history; and patient has not had a liver transplant; and patient will not receive concomitant prophylactic hemin while on Givlaari; and treatment is prescribed by or in consu [...]
Scenesse (afamelanotide) is proven and medically necessary for the treatment of erythropoietic protoporphyria (EPP) when all the following criteria are met:

CGS-J15-L40325, Allergy Diagnostic Testing

J15

CGS-J18-L40325, Allergy Diagnostic Testing

J18

NGS-J6-L40329, Allergy Diagnostic Testing

NGS-JK-L40329, Allergy Diagnostic Testing

UHC-POL-scenesse

Ask Backwork about documentation requirements, denial risks, or coverage in your state.